当前位置: X-MOL 学术Am. J. Alzheimers Dis. Other Demen. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
American Journal of Alzheimer's Disease and other Dementias ( IF 2.7 ) Pub Date : 2019-05-07 , DOI: 10.1177/1533317519848237
Suk Ling Ma 1 , Nelson Leung Sang Tang 2, 3, 4 , Karen Hong Yun Wat 5 , Jenny Hoi Yin Tang 5 , Ka Hin Lau 6 , Chun Bon Law 7 , John Chiu 7 , Cindy Chi Woon Tam 8 , Tin Keung Poon 9 , Ka Leung Lin 10 , Carolyn Poey Lyn Kng 10 , Hing Leung Kong 10 , Tak Yeung Chan 11 , Wai Chi Chan 6 , Linda Chiu Wa Lam 1
Affiliation  

Alzheimer's disease (AD) is the most prevalent form of dementia, and age is strongly associated with the incidence of AD. This study aimed to investigate the association between the genotypes of CYP2D6, CYP3A4, and CYP2C9 genes to the clinical efficacy and tolerability of cholinesterase inhibitors (ChEIs) in Chinese patients with AD. One hundred seventy-nine patients with AD with newly prescribed with ChEIs were recruited. The clinical response and tolerability were evaluated at baseline, 3rd-, 6th-, and 12th-month follow-ups and were compared according to their genotypes of CYP2D6, CYP3A4, and CYP2C9. Among patients prescribed with donepezil/galantamine, CYP2D6*10 carriers showed significantly less side effects (P = .009). CYP2D6*10 carriers responded better to ChEIs and resulted in better improvement in Alzheimer's Disease Assessment Scale-Cognitive subscale (P = .027) and Mini-Mental State Examination (P = .012). Further study is required to replicate the finding, and it might be useful for clinicians to decide the medication based on the patients' CYP genotypes.
更新日期:2019-11-01
down
wechat
bug